Molecular subtyping and improved treatment of neurodevelopmental disease

Holly Stessman, Tychele N. Turner, Evan E. Eichler

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The next-generation sequencing revolution has substantially increased our understanding of the mutated genes that underlie complex neurodevelopmental disease. Exome sequencing has enabled us to estimate the number of genes involved in the etiology of neurodevelopmental disease, whereas targeted sequencing approaches have provided the means for quick and cost-effective sequencing of thousands of patient samples to assess the significance of individual genes. By leveraging such technologies and clinical exome sequencing, a genotype-first approach has emerged in which patients with a common genotype are first identified and then clinically reassessed as a group. This approach has proven a powerful methodology for refining disease subtypes. We propose that the molecular characterization of these genetic subtypes has important implications for diagnostics and also for future drug development. Classifying patients into subgroups with a common genetic etiology and applying treatments tailored to the specific molecular defect they carry is likely to improve management of neurodevelopmental disease in the future.

Original languageEnglish (US)
Article number22
JournalGenome Medicine
Volume8
Issue number1
DOIs
StatePublished - Feb 25 2016
Externally publishedYes

Fingerprint

Exome
Genotype
Genes
Disease Management
Molecular Biology
Therapeutics
Technology
Costs and Cost Analysis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Molecular subtyping and improved treatment of neurodevelopmental disease. / Stessman, Holly; Turner, Tychele N.; Eichler, Evan E.

In: Genome Medicine, Vol. 8, No. 1, 22, 25.02.2016.

Research output: Contribution to journalArticle

Stessman, Holly ; Turner, Tychele N. ; Eichler, Evan E. / Molecular subtyping and improved treatment of neurodevelopmental disease. In: Genome Medicine. 2016 ; Vol. 8, No. 1.
@article{4a22a6fbe2624c56a718a2fdf89e3895,
title = "Molecular subtyping and improved treatment of neurodevelopmental disease",
abstract = "The next-generation sequencing revolution has substantially increased our understanding of the mutated genes that underlie complex neurodevelopmental disease. Exome sequencing has enabled us to estimate the number of genes involved in the etiology of neurodevelopmental disease, whereas targeted sequencing approaches have provided the means for quick and cost-effective sequencing of thousands of patient samples to assess the significance of individual genes. By leveraging such technologies and clinical exome sequencing, a genotype-first approach has emerged in which patients with a common genotype are first identified and then clinically reassessed as a group. This approach has proven a powerful methodology for refining disease subtypes. We propose that the molecular characterization of these genetic subtypes has important implications for diagnostics and also for future drug development. Classifying patients into subgroups with a common genetic etiology and applying treatments tailored to the specific molecular defect they carry is likely to improve management of neurodevelopmental disease in the future.",
author = "Holly Stessman and Turner, {Tychele N.} and Eichler, {Evan E.}",
year = "2016",
month = "2",
day = "25",
doi = "10.1186/s13073-016-0278-z",
language = "English (US)",
volume = "8",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Molecular subtyping and improved treatment of neurodevelopmental disease

AU - Stessman, Holly

AU - Turner, Tychele N.

AU - Eichler, Evan E.

PY - 2016/2/25

Y1 - 2016/2/25

N2 - The next-generation sequencing revolution has substantially increased our understanding of the mutated genes that underlie complex neurodevelopmental disease. Exome sequencing has enabled us to estimate the number of genes involved in the etiology of neurodevelopmental disease, whereas targeted sequencing approaches have provided the means for quick and cost-effective sequencing of thousands of patient samples to assess the significance of individual genes. By leveraging such technologies and clinical exome sequencing, a genotype-first approach has emerged in which patients with a common genotype are first identified and then clinically reassessed as a group. This approach has proven a powerful methodology for refining disease subtypes. We propose that the molecular characterization of these genetic subtypes has important implications for diagnostics and also for future drug development. Classifying patients into subgroups with a common genetic etiology and applying treatments tailored to the specific molecular defect they carry is likely to improve management of neurodevelopmental disease in the future.

AB - The next-generation sequencing revolution has substantially increased our understanding of the mutated genes that underlie complex neurodevelopmental disease. Exome sequencing has enabled us to estimate the number of genes involved in the etiology of neurodevelopmental disease, whereas targeted sequencing approaches have provided the means for quick and cost-effective sequencing of thousands of patient samples to assess the significance of individual genes. By leveraging such technologies and clinical exome sequencing, a genotype-first approach has emerged in which patients with a common genotype are first identified and then clinically reassessed as a group. This approach has proven a powerful methodology for refining disease subtypes. We propose that the molecular characterization of these genetic subtypes has important implications for diagnostics and also for future drug development. Classifying patients into subgroups with a common genetic etiology and applying treatments tailored to the specific molecular defect they carry is likely to improve management of neurodevelopmental disease in the future.

UR - http://www.scopus.com/inward/record.url?scp=84959117495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959117495&partnerID=8YFLogxK

U2 - 10.1186/s13073-016-0278-z

DO - 10.1186/s13073-016-0278-z

M3 - Article

C2 - 26917491

AN - SCOPUS:84959117495

VL - 8

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 1

M1 - 22

ER -